LFCR Stock Analysis: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$3.81
0.15 (4.10%)
▲
5d:
-5.93%
30d:
-47.08%
90d:
-54.1%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Mar 16, 2026
0d
Smart Money Accumulation
LFCR is down 9.0% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 573 OI. Call ratio: 100% View Scanner →
Strength: 9.5/10
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LFCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LFCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $3.81, which is considered oversold relative to its 30-day fair value range of $4.39 to $7.35.
Technical Outlook: Technically, LFCR is in a downtrend. Immediate support is located at $3.64, while resistance sits at $4.79. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+77.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LFCR is in a downtrend. Immediate support is located at $3.64, while resistance sits at $4.79. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.50 (+77.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.39 -
$7.35
Company Quality Score
47/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 77.6% below Wall St target ($6.50)
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$4.39 -
$7.35
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.64
Resistance Level
$4.79
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.72
Wall Street Target
$6.50
(+77.6%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: March 30, 2026 12:18 PM ET
Data refreshes hourly during market hours. Next update: 1:18 PM
Data refreshes hourly during market hours. Next update: 1:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
